

Patient Group Direction Addendum

This document provides an addendum to the IM Influenza PGD V06.00, PHE publications gateway number: 2015270, valid from 1 September 2018 to 31 March 2019.

In the criteria for exclusion, on page 7, bullet point 6, the text is to include the revised text as emboldened below.

have received a complete dose of the recommended influenza vaccine for the current season, unless they are individuals aged 6 months to less than 9 years in a clinical risk group category listed in <u>Chapter 19</u> of the "The Green Book" who should, in the first season they are vaccinated against influenza, receive a second dose of an appropriate influenza vaccine at least 4 weeks after the first dose

This addendum is approved by the following health professionals on behalf of Public Health England:

Developed by:	Name	Signature	Date
Pharmacist (Lead Author)	Elizabeth Graham Lead Pharmacist Immunisation and Countermeasures, PHE	Elaha	02/10/2018
Doctor	Richard Pebody Consultant Medical Epidemiologist, Immunisation and Countermeasures, PHE	Kalendy	28/09/2018
Registered Nurse (Chair of Expert Panel)	David Green Nurse Consultant – Immunisations and Countermeasures, PHE	DGieen.	02/10/2018

This addendum has been approved by the PHE Medicines Management Group and the PHE Quality and Clinical Governance Delivery Board.

NHS England Hampshire and Thames Valley (HTV) authorises the continued use of IM Influenza PGD V06.00 with this addendum by the services or providers listed below:

Authorised for use by the following organisations and/or services

All NHS England HTV directly commissioned immunisation services.

In addition, the PGD may be adopted by provider organisations (providing NHS immunisation and vaccination services) working within the HTV geography. Where this occurs, provider organisations should have this PGD signed off by their governance lead prior to use. Provider organisation staff will be expected to follow local policies and procedures.

Organisational approval					
Role	Name	Sign	Date		
Deputy Medical Director	Dr Ljuba Stirzaker	D. Gisa Sril	23/10/18		